Commerzbank Aktiengesellschaft FI Has $3.53 Million Stock Position in Becton, Dickinson and Company $BDX

Commerzbank Aktiengesellschaft FI raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 55.0% in the third quarter, Holdings Channel reports. The institutional investor owned 18,844 shares of the medical instruments supplier’s stock after buying an additional 6,689 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Becton, Dickinson and Company were worth $3,527,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. SOA Wealth Advisors LLC. raised its stake in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc increased its holdings in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. Grey Fox Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $32,000. Bank of Jackson Hole Trust lifted its stake in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the period. Finally, CVA Family Office LLC grew its position in Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 97 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,662 shares of company stock valued at $535,246 over the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 2.0%

Shares of Becton, Dickinson and Company stock opened at $201.84 on Friday. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The stock has a market capitalization of $57.51 billion, a P/E ratio of 34.62, a price-to-earnings-growth ratio of 2.23 and a beta of 0.23. The company has a 50-day simple moving average of $197.40 and a 200 day simple moving average of $190.42. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were given a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Analyst Ratings Changes

Several research firms have commented on BDX. Jefferies Financial Group upped their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Piper Sandler lowered their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.